nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP1A2—chronic obstructive pulmonary disease	0.381	1	CbGaD
Ondansetron—CYP2E1—Aminophylline—chronic obstructive pulmonary disease	0.0579	0.152	CbGbCtD
Ondansetron—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0355	0.0935	CbGbCtD
Ondansetron—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0355	0.0935	CbGbCtD
Ondansetron—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0335	0.0882	CbGbCtD
Ondansetron—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0325	0.0855	CbGbCtD
Ondansetron—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0325	0.0855	CbGbCtD
Ondansetron—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0289	0.0762	CbGbCtD
Ondansetron—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0272	0.0717	CbGbCtD
Ondansetron—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0269	0.0708	CbGbCtD
Ondansetron—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0184	0.0484	CbGbCtD
Ondansetron—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0175	0.0462	CbGbCtD
Ondansetron—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0156	0.0412	CbGbCtD
Ondansetron—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00918	0.0242	CbGbCtD
Ondansetron—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00867	0.0228	CbGbCtD
Ondansetron—Alosetron—CYP1A2—chronic obstructive pulmonary disease	0.00434	1	CrCbGaD
Ondansetron—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000358	0.00213	CcSEcCtD
Ondansetron—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000357	0.00212	CcSEcCtD
Ondansetron—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000356	0.00212	CcSEcCtD
Ondansetron—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.00211	CcSEcCtD
Ondansetron—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000353	0.0021	CcSEcCtD
Ondansetron—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000346	0.00206	CcSEcCtD
Ondansetron—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000341	0.00203	CcSEcCtD
Ondansetron—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000341	0.00203	CcSEcCtD
Ondansetron—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000339	0.00202	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000338	0.00201	CcSEcCtD
Ondansetron—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000338	0.00201	CcSEcCtD
Ondansetron—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000338	0.00201	CcSEcCtD
Ondansetron—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000335	0.00199	CcSEcCtD
Ondansetron—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000335	0.00199	CcSEcCtD
Ondansetron—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000334	0.00199	CcSEcCtD
Ondansetron—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000333	0.00198	CcSEcCtD
Ondansetron—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000333	0.00198	CcSEcCtD
Ondansetron—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000331	0.00197	CcSEcCtD
Ondansetron—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000328	0.00196	CcSEcCtD
Ondansetron—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000328	0.00196	CcSEcCtD
Ondansetron—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.000328	0.00195	CcSEcCtD
Ondansetron—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000328	0.00195	CcSEcCtD
Ondansetron—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000326	0.00194	CcSEcCtD
Ondansetron—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000322	0.00192	CcSEcCtD
Ondansetron—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000322	0.00192	CcSEcCtD
Ondansetron—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000322	0.00192	CcSEcCtD
Ondansetron—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000319	0.0019	CcSEcCtD
Ondansetron—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000319	0.0019	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000318	0.00189	CcSEcCtD
Ondansetron—Cough—Formoterol—chronic obstructive pulmonary disease	0.000318	0.00189	CcSEcCtD
Ondansetron—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000318	0.00189	CcSEcCtD
Ondansetron—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00188	CcSEcCtD
Ondansetron—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000315	0.00188	CcSEcCtD
Ondansetron—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000315	0.00187	CcSEcCtD
Ondansetron—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000314	0.00187	CcSEcCtD
Ondansetron—Cough—Montelukast—chronic obstructive pulmonary disease	0.000311	0.00185	CcSEcCtD
Ondansetron—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00031	0.00185	CcSEcCtD
Ondansetron—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00031	0.00185	CcSEcCtD
Ondansetron—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00031	0.00185	CcSEcCtD
Ondansetron—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00031	0.00185	CcSEcCtD
Ondansetron—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000309	0.00184	CcSEcCtD
Ondansetron—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000309	0.00184	CcSEcCtD
Ondansetron—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000309	0.00184	CcSEcCtD
Ondansetron—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000309	0.00184	CcSEcCtD
Ondansetron—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000309	0.00184	CcSEcCtD
Ondansetron—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00184	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000308	0.00183	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000308	0.00183	CcSEcCtD
Ondansetron—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000306	0.00182	CcSEcCtD
Ondansetron—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000306	0.00182	CcSEcCtD
Ondansetron—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000304	0.00181	CcSEcCtD
Ondansetron—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.00181	CcSEcCtD
Ondansetron—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000303	0.00181	CcSEcCtD
Ondansetron—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000303	0.0018	CcSEcCtD
Ondansetron—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.0018	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000302	0.0018	CcSEcCtD
Ondansetron—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000301	0.00179	CcSEcCtD
Ondansetron—Cough—Salbutamol—chronic obstructive pulmonary disease	0.0003	0.00179	CcSEcCtD
Ondansetron—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000297	0.00177	CcSEcCtD
Ondansetron—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000297	0.00177	CcSEcCtD
Ondansetron—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000293	0.00174	CcSEcCtD
Ondansetron—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000293	0.00174	CcSEcCtD
Ondansetron—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.00174	CcSEcCtD
Ondansetron—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000291	0.00174	CcSEcCtD
Ondansetron—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000291	0.00174	CcSEcCtD
Ondansetron—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000291	0.00173	CcSEcCtD
Ondansetron—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000291	0.00173	CcSEcCtD
Ondansetron—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00173	CcSEcCtD
Ondansetron—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00173	CcSEcCtD
Ondansetron—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000289	0.00172	CcSEcCtD
Ondansetron—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000289	0.00172	CcSEcCtD
Ondansetron—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000289	0.00172	CcSEcCtD
Ondansetron—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000288	0.00171	CcSEcCtD
Ondansetron—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.0017	CcSEcCtD
Ondansetron—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000286	0.0017	CcSEcCtD
Ondansetron—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000283	0.00168	CcSEcCtD
Ondansetron—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00167	CcSEcCtD
Ondansetron—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00165	CcSEcCtD
Ondansetron—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00165	CcSEcCtD
Ondansetron—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000276	0.00164	CcSEcCtD
Ondansetron—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000276	0.00164	CcSEcCtD
Ondansetron—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000275	0.00164	CcSEcCtD
Ondansetron—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.00163	CcSEcCtD
Ondansetron—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00162	CcSEcCtD
Ondansetron—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000271	0.00162	CcSEcCtD
Ondansetron—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000267	0.00159	CcSEcCtD
Ondansetron—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.00158	CcSEcCtD
Ondansetron—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000265	0.00158	CcSEcCtD
Ondansetron—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.00157	CcSEcCtD
Ondansetron—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000264	0.00157	CcSEcCtD
Ondansetron—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00156	CcSEcCtD
Ondansetron—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000261	0.00156	CcSEcCtD
Ondansetron—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000261	0.00155	CcSEcCtD
Ondansetron—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000259	0.00154	CcSEcCtD
Ondansetron—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000258	0.00154	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.00153	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000257	0.00153	CcSEcCtD
Ondansetron—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000256	0.00153	CcSEcCtD
Ondansetron—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.00153	CcSEcCtD
Ondansetron—Pain—Formoterol—chronic obstructive pulmonary disease	0.000254	0.00151	CcSEcCtD
Ondansetron—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000254	0.00151	CcSEcCtD
Ondansetron—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000254	0.00151	CcSEcCtD
Ondansetron—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000254	0.00151	CcSEcCtD
Ondansetron—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.0015	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000251	0.0015	CcSEcCtD
Ondansetron—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000251	0.00149	CcSEcCtD
Ondansetron—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00149	CcSEcCtD
Ondansetron—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.00149	CcSEcCtD
Ondansetron—Pain—Montelukast—chronic obstructive pulmonary disease	0.000249	0.00148	CcSEcCtD
Ondansetron—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000249	0.00148	CcSEcCtD
Ondansetron—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000248	0.00148	CcSEcCtD
Ondansetron—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000247	0.00147	CcSEcCtD
Ondansetron—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000246	0.00147	CcSEcCtD
Ondansetron—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000246	0.00146	CcSEcCtD
Ondansetron—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000245	0.00146	CcSEcCtD
Ondansetron—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000245	0.00146	CcSEcCtD
Ondansetron—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000245	0.00146	CcSEcCtD
Ondansetron—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000244	0.00145	CcSEcCtD
Ondansetron—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000243	0.00145	CcSEcCtD
Ondansetron—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000243	0.00145	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00144	CcSEcCtD
Ondansetron—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00144	CcSEcCtD
Ondansetron—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00024	0.00143	CcSEcCtD
Ondansetron—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00024	0.00143	CcSEcCtD
Ondansetron—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000238	0.00142	CcSEcCtD
Ondansetron—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000236	0.00141	CcSEcCtD
Ondansetron—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.00141	CcSEcCtD
Ondansetron—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.0014	CcSEcCtD
Ondansetron—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.0014	CcSEcCtD
Ondansetron—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000235	0.0014	CcSEcCtD
Ondansetron—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000235	0.0014	CcSEcCtD
Ondansetron—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000234	0.00139	CcSEcCtD
Ondansetron—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000232	0.00138	CcSEcCtD
Ondansetron—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000232	0.00138	CcSEcCtD
Ondansetron—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000231	0.00138	CcSEcCtD
Ondansetron—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000231	0.00138	CcSEcCtD
Ondansetron—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000231	0.00137	CcSEcCtD
Ondansetron—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.00137	CcSEcCtD
Ondansetron—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00137	CcSEcCtD
Ondansetron—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00137	CcSEcCtD
Ondansetron—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00137	CcSEcCtD
Ondansetron—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000228	0.00136	CcSEcCtD
Ondansetron—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.00135	CcSEcCtD
Ondansetron—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.00133	CcSEcCtD
Ondansetron—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00132	CcSEcCtD
Ondansetron—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00132	CcSEcCtD
Ondansetron—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000219	0.0013	CcSEcCtD
Ondansetron—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.0013	CcSEcCtD
Ondansetron—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.0013	CcSEcCtD
Ondansetron—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000217	0.00129	CcSEcCtD
Ondansetron—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000214	0.00128	CcSEcCtD
Ondansetron—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00127	CcSEcCtD
Ondansetron—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00127	CcSEcCtD
Ondansetron—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00021	0.00125	CcSEcCtD
Ondansetron—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00021	0.00125	CcSEcCtD
Ondansetron—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000209	0.00124	CcSEcCtD
Ondansetron—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00123	CcSEcCtD
Ondansetron—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000206	0.00123	CcSEcCtD
Ondansetron—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00121	CcSEcCtD
Ondansetron—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00121	CcSEcCtD
Ondansetron—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000202	0.0012	CcSEcCtD
Ondansetron—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.0012	CcSEcCtD
Ondansetron—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00119	CcSEcCtD
Ondansetron—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00118	CcSEcCtD
Ondansetron—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00117	CcSEcCtD
Ondansetron—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00117	CcSEcCtD
Ondansetron—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00117	CcSEcCtD
Ondansetron—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00115	CcSEcCtD
Ondansetron—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00114	CcSEcCtD
Ondansetron—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000189	0.00113	CcSEcCtD
Ondansetron—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.00113	CcSEcCtD
Ondansetron—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00112	CcSEcCtD
Ondansetron—Rash—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00112	CcSEcCtD
Ondansetron—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00111	CcSEcCtD
Ondansetron—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00111	CcSEcCtD
Ondansetron—Headache—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00111	CcSEcCtD
Ondansetron—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00111	CcSEcCtD
Ondansetron—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.00111	CcSEcCtD
Ondansetron—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.0011	CcSEcCtD
Ondansetron—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000185	0.0011	CcSEcCtD
Ondansetron—Rash—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00109	CcSEcCtD
Ondansetron—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000183	0.00109	CcSEcCtD
Ondansetron—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000183	0.00109	CcSEcCtD
Ondansetron—Headache—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00109	CcSEcCtD
Ondansetron—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000181	0.00108	CcSEcCtD
Ondansetron—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.00018	0.00107	CcSEcCtD
Ondansetron—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.00018	0.00107	CcSEcCtD
Ondansetron—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00106	CcSEcCtD
Ondansetron—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000178	0.00106	CcSEcCtD
Ondansetron—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00105	CcSEcCtD
Ondansetron—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000177	0.00105	CcSEcCtD
Ondansetron—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00105	CcSEcCtD
Ondansetron—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00105	CcSEcCtD
Ondansetron—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.00103	CcSEcCtD
Ondansetron—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.00102	CcSEcCtD
Ondansetron—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000998	CcSEcCtD
Ondansetron—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000166	0.000988	CcSEcCtD
Ondansetron—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000985	CcSEcCtD
Ondansetron—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000165	0.00098	CcSEcCtD
Ondansetron—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000161	0.000958	CcSEcCtD
Ondansetron—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000158	0.000943	CcSEcCtD
Ondansetron—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.000935	CcSEcCtD
Ondansetron—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000916	CcSEcCtD
Ondansetron—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00091	CcSEcCtD
Ondansetron—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000889	CcSEcCtD
Ondansetron—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000885	CcSEcCtD
Ondansetron—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000876	CcSEcCtD
Ondansetron—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00086	CcSEcCtD
Ondansetron—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000853	CcSEcCtD
Ondansetron—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000819	CcSEcCtD
Ondansetron—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000804	CcSEcCtD
Ondansetron—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000792	CcSEcCtD
Ondansetron—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.00079	CcSEcCtD
Ondansetron—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000784	CcSEcCtD
Ondansetron—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000131	0.00078	CcSEcCtD
Ondansetron—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000769	CcSEcCtD
Ondansetron—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000765	CcSEcCtD
Ondansetron—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000761	CcSEcCtD
Ondansetron—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00075	CcSEcCtD
Ondansetron—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000739	CcSEcCtD
Ondansetron—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000724	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000721	CcSEcCtD
Ondansetron—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000718	CcSEcCtD
Ondansetron—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000706	CcSEcCtD
Ondansetron—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000696	CcSEcCtD
Ondansetron—Shock—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000685	CcSEcCtD
Ondansetron—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000683	CcSEcCtD
Ondansetron—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00068	CcSEcCtD
Ondansetron—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000676	CcSEcCtD
Ondansetron—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000634	CcSEcCtD
Ondansetron—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000625	CcSEcCtD
Ondansetron—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000604	CcSEcCtD
Ondansetron—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000604	CcSEcCtD
Ondansetron—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000101	0.0006	CcSEcCtD
Ondansetron—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.0006	CcSEcCtD
Ondansetron—Constipation—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000595	CcSEcCtD
Ondansetron—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	9.64e-05	0.000574	CcSEcCtD
Ondansetron—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	9.56e-05	0.000569	CcSEcCtD
Ondansetron—Urticaria—Prednisone—chronic obstructive pulmonary disease	9.29e-05	0.000553	CcSEcCtD
Ondansetron—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	9.25e-05	0.00055	CcSEcCtD
Ondansetron—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	9.25e-05	0.00055	CcSEcCtD
Ondansetron—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	8.62e-05	0.000513	CcSEcCtD
Ondansetron—Asthenia—Prednisone—chronic obstructive pulmonary disease	8.39e-05	0.0005	CcSEcCtD
Ondansetron—Pruritus—Prednisone—chronic obstructive pulmonary disease	8.28e-05	0.000493	CcSEcCtD
Ondansetron—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	8e-05	0.000476	CcSEcCtD
Ondansetron—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.74e-05	0.00046	CcSEcCtD
Ondansetron—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.44e-05	0.000443	CcSEcCtD
Ondansetron—Rash—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000439	CcSEcCtD
Ondansetron—Dermatitis—Prednisone—chronic obstructive pulmonary disease	7.37e-05	0.000439	CcSEcCtD
Ondansetron—Headache—Prednisone—chronic obstructive pulmonary disease	7.33e-05	0.000436	CcSEcCtD
Ondansetron—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.2e-05	0.000625	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.17e-05	0.00062	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.17e-05	0.000619	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.16e-05	0.000619	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.15e-05	0.000617	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.14e-05	0.000616	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.13e-05	0.000614	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.11e-05	0.000611	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.08e-05	0.000607	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.08e-05	0.000607	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.05e-05	0.000602	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	4.02e-05	0.000597	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.01e-05	0.000597	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.98e-05	0.000592	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.97e-05	0.00059	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.95e-05	0.000587	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.95e-05	0.000587	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	3.94e-05	0.000586	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.93e-05	0.000584	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.93e-05	0.000584	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.91e-05	0.000582	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.89e-05	0.000579	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.89e-05	0.000578	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.89e-05	0.000578	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.87e-05	0.000576	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.82e-05	0.000568	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.76e-05	0.000559	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.73e-05	0.000555	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.73e-05	0.000554	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.65e-05	0.000542	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.58e-05	0.000533	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.58e-05	0.000533	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.56e-05	0.000529	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.53e-05	0.000525	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.51e-05	0.000522	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.49e-05	0.000519	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.46e-05	0.000515	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.45e-05	0.000513	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.42e-05	0.000509	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.41e-05	0.000507	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.39e-05	0.000504	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.38e-05	0.000502	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.37e-05	0.000502	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.33e-05	0.000495	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.26e-05	0.000485	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.25e-05	0.000483	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.22e-05	0.000479	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.2e-05	0.000476	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.18e-05	0.000472	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.04e-05	0.000452	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.03e-05	0.000451	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.99e-05	0.000445	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.99e-05	0.000444	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.98e-05	0.000444	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.95e-05	0.000439	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.95e-05	0.000438	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GC—chronic obstructive pulmonary disease	2.91e-05	0.000433	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.9e-05	0.000432	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	2.9e-05	0.000432	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.87e-05	0.000426	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.78e-05	0.000413	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.78e-05	0.000413	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.78e-05	0.000413	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.75e-05	0.000408	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.72e-05	0.000405	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.71e-05	0.000404	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.71e-05	0.000403	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.7e-05	0.000402	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.7e-05	0.000401	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.64e-05	0.000392	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.63e-05	0.00039	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.6e-05	0.000387	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.6e-05	0.000387	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.57e-05	0.000382	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.56e-05	0.000381	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.54e-05	0.000378	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.49e-05	0.000371	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.48e-05	0.000368	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.45e-05	0.000365	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.45e-05	0.000364	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.38e-05	0.000354	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.33e-05	0.000346	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.31e-05	0.000343	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.27e-05	0.000338	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.26e-05	0.000337	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.25e-05	0.000334	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.24e-05	0.000333	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.21e-05	0.000329	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.19e-05	0.000326	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	2.17e-05	0.000322	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.12e-05	0.000316	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.12e-05	0.000315	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.12e-05	0.000315	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.1e-05	0.000313	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.09e-05	0.000311	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.09e-05	0.00031	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.06e-05	0.000307	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.05e-05	0.000304	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.04e-05	0.000303	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.03e-05	0.000302	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.01e-05	0.0003	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.01e-05	0.000299	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	1.98e-05	0.000294	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.94e-05	0.000288	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.93e-05	0.000288	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.92e-05	0.000285	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.92e-05	0.000285	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.9e-05	0.000283	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.89e-05	0.000281	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.82e-05	0.000271	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.82e-05	0.000271	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.8e-05	0.000267	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.79e-05	0.000267	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.76e-05	0.000261	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.75e-05	0.00026	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.74e-05	0.000259	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.67e-05	0.000248	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.64e-05	0.000243	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.63e-05	0.000242	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.59e-05	0.000236	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.59e-05	0.000236	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.57e-05	0.000234	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.57e-05	0.000233	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.57e-05	0.000233	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.56e-05	0.000232	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.55e-05	0.00023	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.54e-05	0.000229	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.52e-05	0.000226	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.52e-05	0.000225	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.5e-05	0.000223	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.5e-05	0.000223	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.47e-05	0.000219	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.44e-05	0.000214	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.43e-05	0.000213	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.43e-05	0.000213	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.43e-05	0.000212	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.42e-05	0.000211	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.4e-05	0.000208	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.39e-05	0.000206	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.38e-05	0.000206	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.37e-05	0.000204	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.36e-05	0.000203	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.35e-05	0.000201	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.33e-05	0.000197	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.32e-05	0.000197	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.32e-05	0.000196	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.32e-05	0.000196	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.3e-05	0.000193	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.27e-05	0.000188	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000187	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.25e-05	0.000187	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.25e-05	0.000186	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.24e-05	0.000184	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.2e-05	0.000179	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.2e-05	0.000178	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.19e-05	0.000176	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.13e-05	0.000168	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.13e-05	0.000168	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.12e-05	0.000166	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.12e-05	0.000166	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.11e-05	0.000166	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.11e-05	0.000164	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.1e-05	0.000164	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.1e-05	0.000163	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.09e-05	0.000162	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.09e-05	0.000161	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.08e-05	0.000161	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.08e-05	0.00016	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.04e-05	0.000155	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.04e-05	0.000154	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.03e-05	0.000153	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.02e-05	0.000151	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.01e-05	0.000151	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.01e-05	0.00015	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.01e-05	0.00015	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.94e-06	0.000148	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.65e-06	0.000143	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.6e-06	0.000143	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.58e-06	0.000142	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.55e-06	0.000142	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.49e-06	0.000141	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.44e-06	0.00014	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.37e-06	0.000139	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.29e-06	0.000138	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.19e-06	0.000137	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	9.01e-06	0.000134	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.81e-06	0.000131	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.77e-06	0.00013	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.62e-06	0.000128	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	8.61e-06	0.000128	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.42e-06	0.000125	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.38e-06	0.000125	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8e-06	0.000119	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.93e-06	0.000118	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.82e-06	0.000116	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.75e-06	0.000115	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.71e-06	0.000115	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.64e-06	0.000114	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.61e-06	0.000113	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.57e-06	0.000113	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.43e-06	0.00011	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.37e-06	0.00011	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	7.29e-06	0.000108	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.23e-06	0.000107	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.18e-06	0.000107	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.12e-06	0.000106	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.06e-06	0.000105	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.84e-06	0.000102	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.81e-06	0.000101	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.75e-06	0.0001	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.72e-06	9.99e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.65e-06	9.89e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.62e-06	9.85e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.53e-06	9.71e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—chronic obstructive pulmonary disease	6.52e-06	9.7e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	6.51e-06	9.68e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.41e-06	9.54e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.28e-06	9.33e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NOS3—chronic obstructive pulmonary disease	6.24e-06	9.28e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	6.23e-06	9.26e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.15e-06	9.15e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.13e-06	9.11e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.1e-06	9.07e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.09e-06	9.05e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.03e-06	8.97e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.8e-06	8.62e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.77e-06	8.58e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.54e-06	8.24e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.43e-06	8.07e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.21e-06	7.74e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.17e-06	7.68e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.11e-06	7.6e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.04e-06	7.5e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.78e-06	7.11e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.73e-06	7.03e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.7e-06	6.98e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.69e-06	6.97e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.63e-06	6.88e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	4.59e-06	6.82e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.56e-06	6.78e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.45e-06	6.62e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.43e-06	6.58e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	4.39e-06	6.53e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.17e-06	6.21e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.94e-06	5.85e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.92e-06	5.83e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.75e-06	5.58e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.6e-06	5.36e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.03e-06	4.5e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.9e-06	4.3e-05	CbGpPWpGaD
